Pharmalittle: We're reading about FDA OK for a lung disease drug, pharma sales in China, and more

Pharmalittle: We're reading about FDA OK for a lung disease drug, pharma sales in China, and more

New study suggests obesity drugs may affect more than just fat, raising questions about muscle strength and organ size after weight loss

FDA OKs treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease

Insmed Inc., a global biopharmaceutical company, announced this week that the U.S. Food and Drug Administration (FDA) has approved Brinsupri (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. The condition is a progressive disease that can lead to permanent lung damage. Brinsupri is the first and only FDA-approved treatment for NCFB, giving…